First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome)

C. Von Stülpnagel, G. Coppola, P. Striano, A. Müller, M. Staudt, G. Kluger

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). Methods: This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF between July 2007 and June 2010. Clinical information was collected via questionnaire. Responder rate was defined as reduction of seizure frequency ≥50% in comparison to four weeks before starting RUF. Maximum follow-up was eighteen months. Results: Responder rates were 7/8 patients after 3 months, 6/8 patients after 6 months and 5/8 patients after 12 months. RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut- Syndrome, for which RUF is particularly effective). Some loss of efficacy was noticed in the long-term observation. Side-effects occurred in two patients. Seizure aggravation was not observed. Conclusion: RUF seems to be a promising therapeutic option in children with MAE. Further studies are warranted to confirm these first observations.

Original languageEnglish
Pages (from-to)459-463
Number of pages5
JournalEuropean Journal of Paediatric Neurology
Volume16
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Orphan Drug Production
Myoclonic Epilepsy
Seizures
Syncope
Multicenter Studies
rufinamide
Observation

Keywords

  • Children
  • Doose syndrome
  • Long-term experience
  • Myoclonic-astatic epilepsy
  • Rufinamide

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health

Cite this

First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). / Von Stülpnagel, C.; Coppola, G.; Striano, P.; Müller, A.; Staudt, M.; Kluger, G.

In: European Journal of Paediatric Neurology, Vol. 16, No. 5, 09.2012, p. 459-463.

Research output: Contribution to journalArticle

Von Stülpnagel, C. ; Coppola, G. ; Striano, P. ; Müller, A. ; Staudt, M. ; Kluger, G. / First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome). In: European Journal of Paediatric Neurology. 2012 ; Vol. 16, No. 5. pp. 459-463.
@article{36f7f11356954eb68d62b640f96ccc3c,
title = "First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome)",
abstract = "Introduction: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). Methods: This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF between July 2007 and June 2010. Clinical information was collected via questionnaire. Responder rate was defined as reduction of seizure frequency ≥50{\%} in comparison to four weeks before starting RUF. Maximum follow-up was eighteen months. Results: Responder rates were 7/8 patients after 3 months, 6/8 patients after 6 months and 5/8 patients after 12 months. RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut- Syndrome, for which RUF is particularly effective). Some loss of efficacy was noticed in the long-term observation. Side-effects occurred in two patients. Seizure aggravation was not observed. Conclusion: RUF seems to be a promising therapeutic option in children with MAE. Further studies are warranted to confirm these first observations.",
keywords = "Children, Doose syndrome, Long-term experience, Myoclonic-astatic epilepsy, Rufinamide",
author = "{Von St{\"u}lpnagel}, C. and G. Coppola and P. Striano and A. M{\"u}ller and M. Staudt and G. Kluger",
year = "2012",
month = "9",
doi = "10.1016/j.ejpn.2011.12.012",
language = "English",
volume = "16",
pages = "459--463",
journal = "European Journal of Paediatric Neurology",
issn = "1090-3798",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - First long-term experience with the orphan drug rufinamide in children with myoclonic-astatic epilepsy (Doose syndrome)

AU - Von Stülpnagel, C.

AU - Coppola, G.

AU - Striano, P.

AU - Müller, A.

AU - Staudt, M.

AU - Kluger, G.

PY - 2012/9

Y1 - 2012/9

N2 - Introduction: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). Methods: This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF between July 2007 and June 2010. Clinical information was collected via questionnaire. Responder rate was defined as reduction of seizure frequency ≥50% in comparison to four weeks before starting RUF. Maximum follow-up was eighteen months. Results: Responder rates were 7/8 patients after 3 months, 6/8 patients after 6 months and 5/8 patients after 12 months. RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut- Syndrome, for which RUF is particularly effective). Some loss of efficacy was noticed in the long-term observation. Side-effects occurred in two patients. Seizure aggravation was not observed. Conclusion: RUF seems to be a promising therapeutic option in children with MAE. Further studies are warranted to confirm these first observations.

AB - Introduction: We evaluated the long-term efficacy and tolerability of the orphan drug rufinamide (RUF) in children with pharmacoresistant myoclonic-astatic epilepsy (MAE, Doose syndrome). Methods: This was a retrospective European multicenter study on eight patients who had started an intention-to-treat trial of RUF between July 2007 and June 2010. Clinical information was collected via questionnaire. Responder rate was defined as reduction of seizure frequency ≥50% in comparison to four weeks before starting RUF. Maximum follow-up was eighteen months. Results: Responder rates were 7/8 patients after 3 months, 6/8 patients after 6 months and 5/8 patients after 12 months. RUF seemed particularly effective in the prevention of myoclonic-astatic seizures (comparable with drop attacks in Lennox-Gastaut- Syndrome, for which RUF is particularly effective). Some loss of efficacy was noticed in the long-term observation. Side-effects occurred in two patients. Seizure aggravation was not observed. Conclusion: RUF seems to be a promising therapeutic option in children with MAE. Further studies are warranted to confirm these first observations.

KW - Children

KW - Doose syndrome

KW - Long-term experience

KW - Myoclonic-astatic epilepsy

KW - Rufinamide

UR - http://www.scopus.com/inward/record.url?scp=84865109115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865109115&partnerID=8YFLogxK

U2 - 10.1016/j.ejpn.2011.12.012

DO - 10.1016/j.ejpn.2011.12.012

M3 - Article

C2 - 22266062

AN - SCOPUS:84865109115

VL - 16

SP - 459

EP - 463

JO - European Journal of Paediatric Neurology

JF - European Journal of Paediatric Neurology

SN - 1090-3798

IS - 5

ER -